Alx Oncology Holdings Inc (ALXO)
$15.74
Insights on Alx Oncology Holdings Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 309.8%
Performance
- $15.10$16.14$15.74
4.07%
Downside
Day's Volatility :6.44%
Upside
2.47%
- $3.94$17.42$15.74
74.97%
Downside
52 Weeks Volatility :77.38%
Upside
9.64%
Returns
| Period | Alx Oncology Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 18.26% | -0.7% | 0.0% |
6 Months | 123.26% | 7.7% | 0.0% |
1 Year | 217.34% | 3.3% | -1.7% |
3 Years | -72.12% | 13.9% | -20.7% |
Highlights
Market Capitalization | 806.4M |
Book Value | $3.8 |
Earnings Per Share (EPS) | -3.74 |
Wall Street Target Price | 20.15 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -38.77% |
Return On Equity TTM | -70.97% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 107.0K |
EBITDA | -169.4M |
Diluted Eps TTM | -3.74 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.27 |
EPS Estimate Next Year | -2.96 |
EPS Estimate Current Quarter | -0.84 |
EPS Estimate Next Quarter | -0.9 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 28.02%
Technicals Summary
Sell
Neutral
Buy
Alx Oncology Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Alx Oncology Holdings Inc | 36.16% | 123.26% | 217.34% | -72.12% | -47.53% |
 Moderna, Inc. | -2.96% | 23.83% | -28.58% | -37.0% | 331.65% |
 Regeneron Pharmaceuticals, Inc. | -6.48% | 11.45% | 11.41% | 80.35% | 169.79% |
 Novo Nordisk A/s | -5.21% | 27.51% | 50.92% | 242.59% | 417.8% |
 Vertex Pharmaceuticals Incorporated | -5.23% | 7.76% | 19.8% | 79.35% | 133.49% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Alx Oncology Holdings Inc | NA | NA | NA | -3.27 | -0.71 | -0.39 | NA | 3.8 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.8 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.3 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Alx Oncology Holdings Inc | Buy | $806.4M | -47.53% | NA | 0.0% |
Moderna, Inc. | Buy | $39.1B | 331.65% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 169.79% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 417.8% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.49% | 28.42 | 36.68% |
Institutional Holdings
venBio Partners LLC
19.34%FMR Inc
14.90%Vivo Capital, LLC
8.41%Cormorant Asset Management, LLC
6.27%Orbimed Advisors, LLC
6.17%BlackRock Inc
4.46%
Corporate Announcements
Alx Oncology Holdings Inc Earnings
Alx Oncology Holdings Inc’s price-to-earnings ratio stands at None
Read More
Company Information
alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com
Organization | Alx Oncology Holdings Inc |
Employees | 72 |
CEO | Dr. Corey S. Goodman Ph.D. |
Industry | Commercial Services |
